Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (251)	5/24/1999 8:29:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 805

Thanks to the Yahoo board for finding this: pbn.com Says the results of pain trial is due out in June. The story was featured in the May 24-30, 1999 issue of Providence Business News. One fellow on the Yahoo board suggested this is like playing at a Casino, but I would disagree. I would say downside is 50% to $1/2, upside is quite a bit higher than 50%--probably a nice spike into the $3's with success, then some clear sailing for the future. But what the odds of sucess are, I have no idea--it feels like a coin flip. The potential payoff is worth the investment. If the worst occurs, there will a chance to recoup if something is salvaged from the Stem Cells portion of the business someday. I got the impression that maybe Aebischer left because the word went around that if the Astra pain trials fail, then parts of the encapsulation program get scrapped-- the Swiss part (?):There are those who believe that if it fails, it may not mean that the encapsulated cell technology fails, but rather some adjustments or further research might be necessary.